Category:

23 February 2022

MODIFICATION OF THE 2022 CORPORATE EVENTS CALENDAR

14 February 2022

THE EUROPEAN UNION AUTHORISES MARKETING OF CFAs AS A NOVEL FOOD

07 February 2022

Buy-back report January 2022

31 January 2022

PHARMANUTRA S.P.A. CONFIRMS STRONG SALES INCREASE

24 January 2022

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

17 January 2022

PHARMANUTRA S.P.A.: NEW LICENCE GRANTED IN THE U.S.A.

14 January 2022

PUBLICATION OF THE 2022 CORPORATE EVENTS CALENDAR

13 January 2022

PHARMANUTRA S.P.A. STRENGTHENS PRESENCE ON TAIWANESE MARKET

02 December 2021

PHARMANUTRA S.P.A. JOINS THE “MSCI WORLD SMALL CAP” AND “FTSE ITALIA MID CAP” INDICES

25 November 2021

PHARMANUTRA GROUP: THREE NEW PATENTS RELEASED

16 November 2021

NEW INTERNATIONAL AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN ARGENTINA

12 November 2021

INTERIM FINANCIAL REPORT AS OF 30 SEPTEMBER 2021

08 November 2021

BOARD OF DIRECTORS APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2021

25 October 2021

PHARMANUTRA S.P.A.: ALESCO SUBSIDIARY OBTAINS PATENT FOR THE NEW SUCROSOMIAL® BERBERINE

21 October 2021

PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PROCESS PATENT IN INDIA

13 October 2021

NEW DISTRIBUTION AGREEMENTS WITH AMERICAN TAIWAN BIOPHARM CO. AND ARGON DRUG STORE

04 October 2021

PHARMANUTRA S.P.A. CONFIRMS GROWTH TREND IN ITALY AND STRONG RECOVERY ON INTERNATIONAL MARKETS

13 September 2021

HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2021

06 September 2021

BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2021

25 August 2021

PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PATENT IN CHINA

21 July 2021

EFSA IN FAVOUR OF AUTHORISING LIPOCET (CETILAR®) AS A NOVEL FOOD

< 1 … 4 5 6 … 12 >